Abstract:Abstract Background Interstitial lung diseases (ILDs) are a diverse group of conditions characterized by inflammation and fibrosis in the lung. In some patients with ILD, a progressive fibrotic phenotype develops, which is associated with an irreversible decline in lung function and a poor prognosis. Main body The pathological mechanisms that underlie this process culminate in fibroblast activation, proliferation, and differentiation into myofibroblasts, which deposit extracellular matrix proteins and result in fibrosis. Upstream of fibroblast activation, epithelial cell injury and immune activation are known initiators of fibrosis progression, with multiple diverse cell types involved. Recent years have seen an increase in our understanding of the complex and interrelated processes that drive fibrosis progression in ILD, in part due to the advent of single-cell RNA sequencing technology and integrative multiomics analyses. Novel pathological mechanisms have been identified, which represent new targets for drugs currently in clinical development. These include phosphodiesterase 4 inhibitors and other molecules that act on intracellular cyclic adenosine monophosphate signaling, as well as inhibitors of the autotaxin-lysophosphatidic acid axis and $$\alpha_v$$ α v integrins. Here, we review current knowledge and recent developments regarding the pathological mechanisms that underlie progressive fibrotic ILD, including potential therapeutic targets. Conclusion Knowledge of the pathological mechanisms that drive progressive fibrosis in patients with ILD has expanded, with the role of alveolar endothelial cells, the immune system, and fibroblasts better elucidated. Drugs that target novel mechanisms hold promise for expanding the future therapeutic armamentarium for progressive fibrotic ILD.

Research and progress on the mechanism of progressive fibrotic interstitial lung disease combined with lung cancer

Abnormal expression of IGF-binding proteins, an initiating event in idiopathic pulmonary fibrosis?

A specific phenotype of interstitial lung disease—progressive pulmonary fibrosis

Research Progress in the Molecular Mechanisms, Therapeutic Targets, and Drug Development of Idiopathic Pulmonary Fibrosis

Current status of research on interstitial lung disease complicated with lung cancer

[Research Progress on Pathogenic Mechanism and Potential Therapeutic Drugs of Idiopathic Pulmonary Fibrosis Complicated with Non-small Cell Lung Cancer]

Progression of fibrosing interstitial lung disease

Pathological mechanisms and novel drug targets in fibrotic interstitial lung disease

Progress in understanding and treating idiopathic pulmonary fibrosis: recent insights and emerging therapies

Advances in the identification and management of progressive pulmonary fibrosis: perspective from Chinese experts

Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)

Molecular Mechanisms of Pulmonary Fibrogenesis and Its Progression to Lung Cancer: A Review

Latest progress on the molecular mechanisms of idiopathic pulmonary fibrosis

Research Progress on Proteomics of Idiopathic Pulmonary Fibrosis

Progress in Treatment of Idiopathic Pulmonary Fibrosis

Interstitial lung disease revisited

The dawn of precision medicine in fibrotic interstitial lung disease

Pathogenesis and clinical therapy of idiopathic pulmonary fibrosis

Research progress in diagnostic methods for idiopathic pulmonary fibrosis

Predicting progressive phenotype in patients with fibrotic interstitial lung disease

Research progress of idiopathic pulmonary fibrosis and its treatment